You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePerphenazine
Accession NumberDB00850  (APRD00429)
TypeSmall Molecule
GroupsApproved
DescriptionAn antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine. [PubChem]
Structure
Thumb
Synonyms
2-(4-[3-(2-chloro-10H-Phenothiazin-10-yl)propyl]-1-piperazinyl)ethanol
2-chloro-10-(3-(4-(2-Hydroxyethyl)piperazin-1-yl)propyl)phenothiazine
4-[3-(2-chloro-10H-Phenothiazin-10-yl)propyl]-1-piperazineethanol
4-[3-(2-Chlorophenothiazin-10-yl)propyl]-1-piperazineethanol
Chlorpiprazine
Etaperazin
Etaperazine
Ethaperazine
gamma-(4-(beta-Hydroxyethyl)piperazin-1-yl)propyl-2-chlorophenothiazine
Perfenazina
Perfenazine
Perphenazin
Perphénazine
Perphenazinum
Trilafon
External Identifiers
  • SC 7105
  • Sch 3940
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Perphenazinetablet16 mgoralAa Pharma Inc1976-12-31Not applicableCanada
Perphenazinetablet8 mgoralAa Pharma Inc1976-12-31Not applicableCanada
Perphenazinetablet4 mgoralAa Pharma Inc1976-12-31Not applicableCanada
Perphenazinetablet2 mgoralAa Pharma Inc1976-12-31Not applicableCanada
Perphenazine 16 Tabtablet16 mgoralPro Doc Limitee1982-12-312010-07-13Canada
Perphenazine 2 Tab 2mgtablet2 mgoralPro Doc Limitee1982-12-312010-07-13Canada
Perphenazine 8 Tab 8mgtablet8 mgoralPro Doc Limitee1982-12-312010-07-13Canada
Perphenazine Tab 2mgtablet2 mgoralD.C. Labs Limited1979-12-312003-07-11Canada
Perphenazine Tab 4mgtablet4 mgoralPro Doc Limitee1982-12-312010-07-13Canada
Perphenazine Tab 4mgtablet4 mgoralD.C. Labs Limited1979-12-312003-07-11Canada
Phenazine 16 Tabtablet16 mgoralIcn Canada Ltd.1974-12-311998-08-13Canada
Phenazine 2 Tabtablet2 mgoralIcn Canada Ltd.1973-12-311998-08-13Canada
Phenazine 4 Tabtablet4 mgoralIcn Canada Ltd.1973-12-311998-08-13Canada
Phenazine 8 Tabtablet8 mgoralIcn Canada Ltd.1974-12-311998-08-13Canada
PMS Perphenazine Concentrate Liq 3.2mg/mlliquid3.2 mgoralPharmascience Inc1988-12-31Not applicableCanada
PMS Perphenazine Tab 16mgtablet16 mgoralPharmascience Inc1987-12-31Not applicableCanada
PMS Perphenazine Tab 2mgtablet2 mgoralPharmascience Inc1987-12-31Not applicableCanada
PMS Perphenazine Tab 4mgtablet4 mgoralPharmascience Inc1987-12-31Not applicableCanada
PMS Perphenazine Tab 8mgtablet8 mgoralPharmascience Inc1987-12-31Not applicableCanada
Trilafon Conc 16mg/5mlliquid16 mgoralSchering Plough Canada Inc1958-12-311997-12-01Canada
Trilafon Inj 5mg/mlsolution5 mgintramuscular; intravenousSchering Plough Canada Inc1958-12-312006-08-01Canada
Trilafon Syr 2mg/5mlsyrup2 mgoralSchering Plough Canada Inc1958-12-311996-11-08Canada
Trilafon Tab 2mgtablet2 mgoralSchering Plough Canada Inc1957-12-312000-07-11Canada
Trilafon Tab 4mgtablet4 mgoralSchering Plough Canada Inc1957-12-311998-11-17Canada
Trilafon Tab 8mgtablet8 mgoralSchering Plough Canada Inc1957-12-311996-09-10Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Perphenazinetablet, film coated4 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Perphenazinetablet, film coated4 mg/1oralContract Pharmacy Services Pa2010-04-07Not applicableUs
Perphenazinetablet, film coated2 mg/1oralSandoz Inc1988-12-08Not applicableUs
Perphenazinetablet, film coated2 mg/1oralQualitest Pharmaceuticals1998-12-31Not applicableUs
Perphenazinetablet, film coated8 mg/1oralREMEDYREPACK INC.2013-03-20Not applicableUs
Perphenazinetablet, film coated2 mg/1oralClinical Solutions Wholesale1998-12-31Not applicableUs
Perphenazinetablet, film coated4 mg/1oralRebel Distributors Corp2010-04-07Not applicableUs
Perphenazinetablet, film coated16 mg/1oralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs
Perphenazinetablet, film coated2 mg/1oralAmerican Health Packaging2014-09-17Not applicableUs
Perphenazinetablet, film coated2 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs1988-12-08Not applicableUs
Perphenazinetablet, sugar coated8 mg/1oralH.J. Harkins Company, Inc.1998-12-31Not applicableUs
Perphenazinetablet, film coated4 mg/1oralREMEDYREPACK INC.2015-09-17Not applicableUs
Perphenazinetablet, film coated4 mg/1oralSandoz Inc1988-12-08Not applicableUs
Perphenazinetablet, film coated8 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Perphenazinetablet, film coated8 mg/1oralContract Pharmacy Services Pa2010-04-07Not applicableUs
Perphenazinetablet, film coated4 mg/1oralQualitest Pharmaceuticals1998-12-31Not applicableUs
Perphenazinetablet, film coated16 mg/1oralREMEDYREPACK INC.2013-03-19Not applicableUs
Perphenazinetablet, film coated4 mg/1oralClinical Solutions Wholesale1998-12-31Not applicableUs
Perphenazinetablet, film coated8 mg/1oralRebel Distributors Corp2010-04-07Not applicableUs
Perphenazinetablet, film coated4 mg/1oralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs
Perphenazinetablet, film coated16 mg/1oralAmerican Health Packaging2014-10-09Not applicableUs
Perphenazinetablet, film coated4 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs1988-12-08Not applicableUs
Perphenazinetablet, sugar coated2 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Perphenazinetablet, film coated2 mg/1oralREMEDYREPACK INC.2015-10-08Not applicableUs
Perphenazinetablet, film coated8 mg/1oralSandoz Inc1988-12-08Not applicableUs
Perphenazinetablet, sugar coated8 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Perphenazinetablet, film coated4 mg/1oralAmerican Health Packaging2012-04-04Not applicableUs
Perphenazinetablet, film coated8 mg/1oralQualitest Pharmaceuticals1998-12-31Not applicableUs
Perphenazinetablet, film coated4 mg/1oralREMEDYREPACK INC.2012-09-26Not applicableUs
Perphenazinetablet, film coated8 mg/1oralClinical Solutions Wholesale1998-12-31Not applicableUs
Perphenazinetablet8 mg/1oralREMEDYREPACK INC.2011-10-192016-03-12Us
Perphenazinetablet, film coated2 mg/1oralState of Florida DOH Central Pharmacy2014-11-01Not applicableUs
Perphenazinetablet, film coated8 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs1988-12-08Not applicableUs
Perphenazinetablet, film coated2 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Perphenazinetablet, film coated2 mg/1oralREMEDYREPACK INC.2015-10-19Not applicableUs
Perphenazinetablet, film coated16 mg/1oralSandoz Inc1988-12-08Not applicableUs
Perphenazinetablet, film coated16 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Perphenazinetablet, film coated8 mg/1oralAmerican Health Packaging2012-05-01Not applicableUs
Perphenazinetablet, film coated16 mg/1oralQualitest Pharmaceuticals1998-12-31Not applicableUs
Perphenazinetablet, film coated8 mg/1oralREMEDYREPACK INC.2013-11-12Not applicableUs
Perphenazinetablet, film coated16 mg/1oralClinical Solutions Wholesale1998-12-31Not applicableUs
Perphenazinetablet, film coated2 mg/1oralCardinal Health1988-12-08Not applicableUs
Perphenazinetablet, film coated4 mg/1oralREMEDYREPACK INC.2013-03-26Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
DecentanMerck
EmesinalNot Available
FentazinMercury
PerphenanTaro
PZCTanabe Mitsubishi Pharma
TrilafonSchering-Plough
TrilifanNot Available
Brand mixtures
NameLabellerIngredients
Apo Peram Tab 2-25Apotex Inc
Apo Peram Tab 3-15Apotex Inc
Elavil Plus TabTriton Pharma Inc
Etrafon 2 10Schering Plough Canada Inc
Etrafon A TabSchering Plough Canada Inc
Etrafon D TabSchering Plough Canada Inc
Etrafon F TabSchering Plough Canada Inc
Perphenazine and Amitriptyline HydrochlorideMylan Pharmaceuticals Inc.
PMS-levazine 2/25 TabPharmascience Inc
PMS-levazine 3/15 TabPharmascience Inc
PMS-levazine 4/25 TabPharmascience Inc
Proavil TabPro Doc Limitee
Triavil TabMerck Frosst Canada & Cie, Merck Frosst Canada & Co.
Salts
Name/CASStructureProperties
Perphenazine enanthate
ThumbNot applicableDBSALT000936
Perphenazine heptanoate
ThumbNot applicableDBSALT000937
Categories
UNIIFTA7XXY4EZ
CAS number58-39-9
WeightAverage: 403.969
Monoisotopic: 403.148510866
Chemical FormulaC21H26ClN3OS
InChI KeyInChIKey=RGCVKNLCSQQDEP-UHFFFAOYSA-N
InChI
InChI=1S/C21H26ClN3OS/c22-17-6-7-21-19(16-17)25(18-4-1-2-5-20(18)27-21)9-3-8-23-10-12-24(13-11-23)14-15-26/h1-2,4-7,16,26H,3,8-15H2
IUPAC Name
2-{4-[3-(2-chloro-10H-phenothiazin-10-yl)propyl]piperazin-1-yl}ethan-1-ol
SMILES
OCCN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenothiazines. These are polycyclic aromatic compounds containing a phenothiazine moiety, which is a linear tricyclic system that consists of a two benzene rings joined by a para-thiazine ring.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzothiazines
Sub ClassPhenothiazines
Direct ParentPhenothiazines
Alternative Parents
Substituents
  • Phenothiazine
  • Alkyldiarylamine
  • Diarylthioether
  • N-alkylpiperazine
  • Chlorobenzene
  • Benzenoid
  • Piperazine
  • 1,4-diazinane
  • Aryl halide
  • Aryl chloride
  • Para-thiazine
  • Tertiary aliphatic amine
  • Tertiary amine
  • 1,2-aminoalcohol
  • Azacycle
  • Thioether
  • Alkanolamine
  • Hydrocarbon derivative
  • Primary alcohol
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Amine
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor use in the management of the manifestations of psychotic disorders and for the control of severe nausea and vomiting in adults.
PharmacodynamicsPerphenazine is a piperazinyl phenothiazine, acts on the central nervous system, and has a greater behavioral potency than other phenothiazine derivatives whose side chains do not contain a piperazine moiety. It is a member of a class of drugs called phenothiazines, which are dopamine D1/D2 receptor antagonists. Perphenazine is 10 to 15 times as potent as chlorpromazine; that means perphenazine is a highly potent antipsychotic. In equivalent doses it has approximately the same frequency and severity of early and late extrapypramidal side-effects compared to Haloperidol.
Mechanism of actionBinds to the dopamine D1 and dopamine D2 receptors and inhibits their activity. The mechanism of the anti-emetic effect is due predominantly to blockage of the dopamine D2 neurotransmitter receptors in the chemoreceptor trigger zone and vomiting centre. Perphenazine also binds the alpha andrenergic receptor. This receptor's action is mediated by association with G proteins that activate a phosphatidylinositol-calcium second messenger system.
Related Articles
AbsorptionAbsolute bioavailability is 40% following oral administration.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Hepatic.

Route of eliminationPerphenazine is extensively metabolized in the liver to a number of metabolites by sulfoxidation, hydroxylation, dealkylation, and glucuronidation.
Half life8-12 hours, but ranges up to 20 hours.
ClearanceNot Available
ToxicitySymptoms of overdose include stupor or coma, and children may have convulsive seizures. Signs of arousal may not occur for 48 hours. Oral LD50=318 mg/kg (rat); IPR LD50=64 mg/kg (mouse)
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9476
Blood Brain Barrier+0.9683
Caco-2 permeable-0.5126
P-glycoprotein substrateSubstrate0.7862
P-glycoprotein inhibitor IInhibitor0.8563
P-glycoprotein inhibitor IIInhibitor0.7689
Renal organic cation transporterInhibitor0.5807
CYP450 2C9 substrateNon-substrate0.7442
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateNon-substrate0.6813
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.9278
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.9089
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7548
Ames testNon AMES toxic0.8093
CarcinogenicityNon-carcinogens0.8836
BiodegradationNot ready biodegradable1.0
Rat acute toxicity3.0725 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7745
hERG inhibition (predictor II)Inhibitor0.7066
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Pharmaceutical assoc inc
  • Schering corp sub schering plough corp
  • Ivax pharmaceuticals inc
  • Sandoz inc
  • Vintage pharmaceuticals inc
Packagers
Dosage forms
FormRouteStrength
Tabletoral16 mg
Tabletoral2 mg
Tabletoral4 mg
Tabletoral8 mg
Tabletoral8 mg/1
Tablet, film coatedoral16 mg/1
Tablet, film coatedoral2 mg/1
Tablet, film coatedoral4 mg/1
Tablet, film coatedoral8 mg/1
Tablet, sugar coatedoral2 mg/1
Tablet, sugar coatedoral8 mg/1
Tabletoral
Tablet, film coatedoral
Liquidoral3.2 mg
Liquidoral16 mg
Solutionintramuscular; intravenous5 mg
Syruporal2 mg
Prices
Unit descriptionCostUnit
Perphenazine 16 mg tablet1.73USD tablet
Perphenazine 8 mg tablet1.28USD tablet
Perphenazine 4 mg tablet1.05USD tablet
Perphenazine 2 mg tablet0.77USD tablet
Apo-Perphenazine 16 mg Tablet0.13USD tablet
Apo-Perphenazine 8 mg Tablet0.09USD tablet
Apo-Perphenazine 4 mg Tablet0.08USD tablet
Apo-Perphenazine 2 mg Tablet0.07USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point97 °CPhysProp
boiling point278-281 °C at 1.00E+00 mm HgPhysProp
water solubility28.3 mg/L (at 24 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP4.20HANSCH,C ET AL. (1995)
logS-4.16ADME Research, USCD
pKa7.94SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.0237 mg/mLALOGPS
logP4.15ALOGPS
logP3.69ChemAxon
logS-4.2ALOGPS
pKa (Strongest Acidic)15.59ChemAxon
pKa (Strongest Basic)8.21ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area29.95 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity116.1 m3·mol-1ChemAxon
Polarizability44.77 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (9.95 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0002-4591100000-97d36958b3e0fe519db6View in MoNA
References
Synthesis Reference

DrugSyn.org

US2860138
General ReferencesNot Available
External Links
ATC CodesN05AB03
AHFS Codes
  • 28:16.08.24
PDB EntriesNot Available
FDA labelDownload (360 KB)
MSDSDownload (74.9 KB)
Interactions
Drug Interactions
Drug
3,4-MethylenedioxyamphetaminePerphenazine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
3,4-MethylenedioxymethamphetaminePerphenazine may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.
5'-Deoxy-5'-MethylthioadenosineThe serum concentration of Perphenazine can be increased when it is combined with 5'-Deoxy-5'-Methylthioadenosine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when Perphenazine is combined with 7-Nitroindazole.
AbirateroneThe serum concentration of Perphenazine can be increased when it is combined with Abiraterone.
AcebutololPerphenazine may increase the hypotensive activities of Acebutolol.
AcepromazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Aceprometazine.
adipiplonThe risk or severity of adverse effects can be increased when Perphenazine is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Agomelatine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Perphenazine is combined with Alfaxalone.
AlfentanilPerphenazine may increase the hypotensive activities of Alfentanil.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Perphenazine.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Perphenazine.
AlphacetylmethadolPerphenazine may increase the hypotensive activities of Alphacetylmethadol.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Perphenazine.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Perphenazine.
AlprenololPerphenazine may increase the hypotensive activities of Alprenolol.
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Perphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Aluminum phosphateAluminum phosphate can cause a decrease in the absorption of Perphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
AmiodaroneThe metabolism of Perphenazine can be decreased when combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Perphenazine is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Perphenazine.
AmobarbitalThe risk or severity of adverse effects can be increased when Perphenazine is combined with Amobarbital.
AmodiaquineThe serum concentration of Perphenazine can be increased when it is combined with Amodiaquine.
AmoxapineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Perphenazine is combined with Amperozide.
AmphetaminePerphenazine may decrease the stimulatory activities of Amphetamine.
AprepitantThe serum concentration of Perphenazine can be increased when it is combined with Aprepitant.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Perphenazine.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Perphenazine.
ArmodafinilThe metabolism of Perphenazine can be decreased when combined with Armodafinil.
ArotinololPerphenazine may increase the hypotensive activities of Arotinolol.
ArtemetherThe serum concentration of Perphenazine can be increased when it is combined with Artemether.
ArtesunateThe serum concentration of Perphenazine can be increased when it is combined with Artesunate.
ArticaineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Asenapine.
AtazanavirThe metabolism of Perphenazine can be decreased when combined with Atazanavir.
AtenololPerphenazine may increase the hypotensive activities of Atenolol.
AtomoxetineThe metabolism of Perphenazine can be decreased when combined with Atomoxetine.
AtovaquoneThe serum concentration of Perphenazine can be increased when it is combined with Atovaquone.
AzaperoneThe risk or severity of adverse effects can be increased when Perphenazine is combined with Azaperone.
AzelastinePerphenazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Perphenazine.
AzithromycinThe metabolism of Perphenazine can be decreased when combined with Azithromycin.
BaclofenThe risk or severity of adverse effects can be increased when Perphenazine is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Perphenazine is combined with Barbital.
BefunololPerphenazine may increase the hypotensive activities of Befunolol.
BenzocaineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Benzocaine.
BenzphetaminePerphenazine may decrease the stimulatory activities of Benzphetamine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Perphenazine is combined with Benzyl alcohol.
BetaxololPerphenazine may increase the hypotensive activities of Betaxolol.
BetaxololThe metabolism of Perphenazine can be decreased when combined with Betaxolol.
BevantololPerphenazine may increase the hypotensive activities of Bevantolol.
BexaroteneThe serum concentration of Perphenazine can be decreased when it is combined with Bexarotene.
BezitramidePerphenazine may increase the hypotensive activities of Bezitramide.
Bismuth SubcitrateBismuth Subcitrate can cause a decrease in the absorption of Perphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
BisoprololPerphenazine may increase the hypotensive activities of Bisoprolol.
BoceprevirThe metabolism of Perphenazine can be decreased when combined with Boceprevir.
BopindololPerphenazine may increase the hypotensive activities of Bopindolol.
BortezomibThe metabolism of Perphenazine can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Perphenazine can be decreased when it is combined with Bosentan.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Perphenazine is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Perphenazine.
BrimonidineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Perphenazine is combined with Bromazepam.
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Perphenazine.
BrompheniramineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Perphenazine is combined with Brotizolam.
BufuralolPerphenazine may increase the hypotensive activities of Bufuralol.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Perphenazine.
BupranololPerphenazine may increase the hypotensive activities of Bupranolol.
BuprenorphinePerphenazine may increase the hypotensive activities of Buprenorphine.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Perphenazine.
BupropionThe metabolism of Perphenazine can be decreased when combined with Bupropion.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Perphenazine.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Perphenazine.
ButacaineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Perphenazine is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Perphenazine is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Perphenazine is combined with Butethal.
ButorphanolPerphenazine may increase the hypotensive activities of Butorphanol.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Perphenazine.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Perphenazine.
CaffeineThe metabolism of Perphenazine can be decreased when combined with Caffeine.
Calcium carbonateCalcium carbonate can cause a decrease in the absorption of Perphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
CapecitabineThe metabolism of Perphenazine can be decreased when combined with Capecitabine.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Perphenazine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Carbinoxamine.
CarfentanilPerphenazine may increase the hypotensive activities of Carfentanil.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Perphenazine.
CarisoprodolThe risk or severity of adverse effects can be increased when Perphenazine is combined with Carisoprodol.
CarteololPerphenazine may increase the hypotensive activities of Carteolol.
CarvedilolPerphenazine may increase the hypotensive activities of Carvedilol.
CelecoxibThe metabolism of Perphenazine can be decreased when combined with Celecoxib.
CeliprololPerphenazine may increase the hypotensive activities of Celiprolol.
CeritinibThe serum concentration of Perphenazine can be increased when it is combined with Ceritinib.
CetirizineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Perphenazine is combined with Chloral hydrate.
ChloramphenicolThe metabolism of Perphenazine can be decreased when combined with Chloramphenicol.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Perphenazine.
ChlormezanoneThe risk or severity of adverse effects can be increased when Perphenazine is combined with Chlormezanone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Chloroprocaine.
ChloroquineThe serum concentration of Perphenazine can be increased when it is combined with Chloroquine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Chlorphenamine.
ChlorphenterminePerphenazine may decrease the stimulatory activities of Chlorphentermine.
ChlorpromazineThe metabolism of Perphenazine can be decreased when combined with Chlorpromazine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Chlorpromazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Perphenazine is combined with Chlorprothixene.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Perphenazine is combined with Chlorzoxazone.
CholecalciferolThe metabolism of Perphenazine can be decreased when combined with Cholecalciferol.
CimetidineThe metabolism of Perphenazine can be decreased when combined with Cimetidine.
CinacalcetThe metabolism of Perphenazine can be decreased when combined with Cinacalcet.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Perphenazine.
CitalopramThe risk or severity of adverse effects can be increased when Perphenazine is combined with Citalopram.
ClarithromycinThe metabolism of Perphenazine can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Perphenazine can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Perphenazine is combined with Clidinium.
ClobazamThe metabolism of Perphenazine can be decreased when combined with Clobazam.
ClobazamThe risk or severity of adverse effects can be increased when Perphenazine is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Perphenazine is combined with clomethiazole.
ClomipramineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Perphenazine is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Clonidine.
ClopidogrelThe metabolism of Perphenazine can be decreased when combined with Clopidogrel.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Perphenazine.
ClotrimazoleThe metabolism of Perphenazine can be decreased when combined with Clotrimazole.
ClozapineThe metabolism of Perphenazine can be decreased when combined with Clozapine.
ClozapineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Clozapine.
CobicistatThe serum concentration of Perphenazine can be increased when it is combined with Cobicistat.
CocaineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Cocaine.
CodeinePerphenazine may increase the hypotensive activities of Codeine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Perphenazine.
ConivaptanThe serum concentration of Perphenazine can be increased when it is combined with Conivaptan.
CrizotinibThe metabolism of Perphenazine can be decreased when combined with Crizotinib.
CyclizineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Perphenazine.
CyclosporineThe metabolism of Perphenazine can be decreased when combined with Cyclosporine.
CyproheptadineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Cyproheptadine.
Cyproterone acetateThe serum concentration of Perphenazine can be decreased when it is combined with Cyproterone acetate.
DabrafenibThe serum concentration of Perphenazine can be decreased when it is combined with Dabrafenib.
DantroleneThe risk or severity of adverse effects can be increased when Perphenazine is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Perphenazine.
DapoxetineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Dapoxetine.
DapsoneThe serum concentration of Perphenazine can be increased when it is combined with Dapsone.
DarifenacinThe metabolism of Perphenazine can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Perphenazine can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Perphenazine can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Perphenazine can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Perphenazine can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when Perphenazine is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Perphenazine is combined with Desflurane.
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Perphenazine.
DesloratadineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Desloratadine.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Perphenazine.
DetomidineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Detomidine.
DexamethasoneThe serum concentration of Perphenazine can be decreased when it is combined with Dexamethasone.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Dexbrompheniramine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Perphenazine.
DextroamphetaminePerphenazine may decrease the stimulatory activities of Dextroamphetamine.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Perphenazine.
DextromoramidePerphenazine may increase the hypotensive activities of Dextromoramide.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Perphenazine.
DextropropoxyphenePerphenazine may increase the hypotensive activities of Dextropropoxyphene.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Perphenazine.
DezocinePerphenazine may increase the hypotensive activities of Dezocine.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Perphenazine.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Perphenazine.
DifenoxinThe risk or severity of adverse effects can be increased when Perphenazine is combined with Difenoxin.
DihydrocodeinePerphenazine may increase the hypotensive activities of Dihydrocodeine.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Perphenazine.
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Perphenazine.
DihydroetorphinePerphenazine may increase the hypotensive activities of Dihydroetorphine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Perphenazine.
DihydromorphinePerphenazine may increase the hypotensive activities of Dihydromorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Perphenazine.
DiltiazemThe metabolism of Perphenazine can be decreased when combined with Diltiazem.
DimenhydrinateThe risk or severity of adverse effects can be increased when Perphenazine is combined with Dimenhydrinate.
DiphenhydramineThe metabolism of Perphenazine can be decreased when combined with Diphenhydramine.
DiphenhydramineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Diphenhydramine.
DiphenoxylatePerphenazine may increase the hypotensive activities of Diphenoxylate.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Perphenazine.
DoramectinThe risk or severity of adverse effects can be increased when Perphenazine is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Perphenazine.
DoxorubicinThe metabolism of Perphenazine can be decreased when combined with Doxorubicin.
DoxycyclineThe serum concentration of Perphenazine can be increased when it is combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Perphenazine.
DoxylamineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Doxylamine.
DPDPEPerphenazine may increase the hypotensive activities of DPDPE.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Perphenazine.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Perphenazine.
DronedaroneThe metabolism of Perphenazine can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Perphenazine.
DrotebanolThe risk or severity of adverse effects can be increased when Perphenazine is combined with Drotebanol.
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Perphenazine.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Perphenazine.
EcgonineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Perphenazine is combined with ECGONINE METHYL ESTER.
EfavirenzThe serum concentration of Perphenazine can be decreased when it is combined with Efavirenz.
EfavirenzThe risk or severity of adverse effects can be increased when Perphenazine is combined with Efavirenz.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Perphenazine.
EliglustatThe metabolism of Perphenazine can be decreased when combined with Eliglustat.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Perphenazine.
EntacaponeThe risk or severity of adverse effects can be increased when Perphenazine is combined with Entacapone.
EnzalutamideThe serum concentration of Perphenazine can be decreased when it is combined with Enzalutamide.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Perphenazine.
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Perphenazine.
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Perphenazine.
ErythromycinThe metabolism of Perphenazine can be decreased when combined with Erythromycin.
EscitalopramThe risk or severity of adverse effects can be increased when Perphenazine is combined with Escitalopram.
Eslicarbazepine acetateThe serum concentration of Perphenazine can be decreased when it is combined with Eslicarbazepine acetate.
EsmololPerphenazine may increase the hypotensive activities of Esmolol.
EsomeprazoleThe metabolism of Perphenazine can be decreased when combined with Esomeprazole.
EstazolamThe risk or severity of adverse effects can be increased when Perphenazine is combined with Estazolam.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Perphenazine.
EthanolPerphenazine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Perphenazine.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Perphenazine.
EthosuximideThe risk or severity of adverse effects can be increased when Perphenazine is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Perphenazine is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Perphenazine is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Perphenazine is combined with Ethyl loflazepate.
EthylmorphinePerphenazine may increase the hypotensive activities of Ethylmorphine.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Perphenazine.
EtidocaineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Perphenazine is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Perphenazine.
EtoperidoneThe risk or severity of adverse effects can be increased when Perphenazine is combined with Etoperidone.
EtorphinePerphenazine may increase the hypotensive activities of Etorphine.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Perphenazine.
EtravirineThe serum concentration of Perphenazine can be decreased when it is combined with Etravirine.
EzogabineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Perphenazine is combined with Felbamate.
FelodipineThe metabolism of Perphenazine can be decreased when combined with Felodipine.
FencamfamineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Fencamfamine.
FenfluramineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Fenfluramine.
FentanylPerphenazine may increase the hypotensive activities of Fentanyl.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Perphenazine.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Perphenazine.
FexofenadineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Perphenazine is combined with Flibanserin.
FloxuridineThe metabolism of Perphenazine can be decreased when combined with Floxuridine.
FluconazoleThe metabolism of Perphenazine can be decreased when combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Perphenazine is combined with Fludiazepam.
FlunarizineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Perphenazine is combined with Flunitrazepam.
FluorouracilThe metabolism of Perphenazine can be decreased when combined with Fluorouracil.
FluoxetineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Perphenazine is combined with Flupentixol.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Perphenazine.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Perphenazine.
FluspirileneThe risk or severity of adverse effects can be increased when Perphenazine is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Perphenazine is combined with Fluticasone Propionate.
FluvastatinThe metabolism of Perphenazine can be decreased when combined with Fluvastatin.
FluvoxamineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Fluvoxamine.
FosamprenavirThe metabolism of Perphenazine can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Perphenazine can be increased when it is combined with Fosaprepitant.
FosphenytoinThe risk or severity of adverse effects can be increased when Perphenazine is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Perphenazine is combined with Fospropofol.
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Perphenazine.
Fusidic AcidThe serum concentration of Perphenazine can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Perphenazine is combined with Gabapentin.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Perphenazine is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Perphenazine is combined with Gamma Hydroxybutyric Acid.
GemfibrozilThe metabolism of Perphenazine can be decreased when combined with Gemfibrozil.
GlutethimideThe risk or severity of adverse effects can be increased when Perphenazine is combined with Glutethimide.
GuanfacineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Perphenazine.
HalofantrineThe serum concentration of Perphenazine can be increased when it is combined with Halofantrine.
HaloperidolThe metabolism of Perphenazine can be decreased when combined with Haloperidol.
HaloperidolThe risk or severity of adverse effects can be increased when Perphenazine is combined with Haloperidol.
HalothaneThe risk or severity of adverse effects can be increased when Perphenazine is combined with Halothane.
HeroinPerphenazine may increase the hypotensive activities of Heroin.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Perphenazine.
HexobarbitalThe risk or severity of adverse effects can be increased when Perphenazine is combined with Hexobarbital.
HydrocodonePerphenazine may increase the hypotensive activities of Hydrocodone.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Perphenazine.
HydromorphonePerphenazine may increase the hypotensive activities of Hydromorphone.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Perphenazine.
Hydroxyamphetamine hydrobromidePerphenazine may decrease the stimulatory activities of Hydroxyamphetamine hydrobromide.
HydroxychloroquineThe serum concentration of Perphenazine can be increased when it is combined with Hydroxychloroquine.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Perphenazine.
HydroxyzineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Hydroxyzine.
IdelalisibThe serum concentration of Perphenazine can be increased when it is combined with Idelalisib.
IloperidoneThe risk or severity of adverse effects can be increased when Perphenazine is combined with Iloperidone.
ImatinibThe metabolism of Perphenazine can be decreased when combined with Imatinib.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Perphenazine.
IndalpineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Indalpine.
IndenololPerphenazine may increase the hypotensive activities of Indenolol.
IndinavirThe metabolism of Perphenazine can be decreased when combined with Indinavir.
IrbesartanThe metabolism of Perphenazine can be decreased when combined with Irbesartan.
IsavuconazoniumThe metabolism of Perphenazine can be decreased when combined with Isavuconazonium.
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Perphenazine.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Perphenazine.
IsoniazidThe metabolism of Perphenazine can be decreased when combined with Isoniazid.
IsradipineThe metabolism of Perphenazine can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Perphenazine can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Perphenazine can be increased when it is combined with Ivacaftor.
KetamineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Ketamine.
KetazolamThe risk or severity of adverse effects can be increased when Perphenazine is combined with Ketazolam.
KetobemidonePerphenazine may increase the hypotensive activities of Ketobemidone.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Perphenazine.
KetoconazoleThe metabolism of Perphenazine can be decreased when combined with Ketoconazole.
LabetalolPerphenazine may increase the hypotensive activities of Labetalol.
LamotrigineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Lamotrigine.
LapatinibThe metabolism of Perphenazine can be decreased when combined with Lapatinib.
LeflunomideThe metabolism of Perphenazine can be decreased when combined with Leflunomide.
LevetiracetamThe risk or severity of adverse effects can be increased when Perphenazine is combined with Levetiracetam.
LevobunololPerphenazine may increase the hypotensive activities of Levobunolol.
LevobupivacaineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Levobupivacaine.
LevocabastineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Perphenazine is combined with Levodopa.
Levomethadyl AcetatePerphenazine may increase the hypotensive activities of Levomethadyl Acetate.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Perphenazine.
LevomilnacipranThe risk or severity of adverse effects can be increased when Perphenazine is combined with Levomilnacipran.
LevorphanolPerphenazine may increase the hypotensive activities of Levorphanol.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Perphenazine.
LidocaineThe metabolism of Perphenazine can be decreased when combined with Lidocaine.
LidocaineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Lidocaine.
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Perphenazine.
LisdexamfetaminePerphenazine may decrease the stimulatory activities of Lisdexamfetamine.
LithiumLithium may increase the neurotoxic activities of Perphenazine.
LithiumThe risk or severity of adverse effects can be increased when Perphenazine is combined with Lithium.
LofentanilPerphenazine may increase the hypotensive activities of Lofentanil.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Perphenazine.
LopinavirThe metabolism of Perphenazine can be decreased when combined with Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Perphenazine.
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Perphenazine.
LosartanThe metabolism of Perphenazine can be decreased when combined with Losartan.
LovastatinThe metabolism of Perphenazine can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Perphenazine.
Lu AA21004The risk or severity of adverse effects can be increased when Perphenazine is combined with Lu AA21004.
LuliconazoleThe serum concentration of Perphenazine can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Perphenazine can be decreased when it is combined with Lumacaftor.
LumefantrineThe serum concentration of Perphenazine can be increased when it is combined with Lumefantrine.
LurasidoneThe risk or severity of adverse effects can be increased when Perphenazine is combined with Lurasidone.
MagaldrateMagaldrate can cause a decrease in the absorption of Perphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium carbonateMagnesium carbonate can cause a decrease in the absorption of Perphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium hydroxideMagnesium hydroxide can cause a decrease in the absorption of Perphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Perphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Perphenazine.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Perphenazine is combined with Magnesium Sulfate.
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Perphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Perphenazine.
MeclizineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Medetomidine.
MefloquineThe serum concentration of Perphenazine can be increased when it is combined with Mefloquine.
MelatoninThe risk or severity of adverse effects can be increased when Perphenazine is combined with Melatonin.
MelperoneThe risk or severity of adverse effects can be increased when Perphenazine is combined with Melperone.
MephenterminePerphenazine may decrease the stimulatory activities of Mephentermine.
MepivacaineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Mepivacaine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Perphenazine.
MequitazinePerphenazine may increase the arrhythmogenic activities of Mequitazine.
MesoridazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Mesoridazine.
MetaxaloneThe risk or severity of adverse effects can be increased when Perphenazine is combined with Metaxalone.
MethadonePerphenazine may increase the hypotensive activities of Methadone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Perphenazine.
Methadyl AcetatePerphenazine may increase the hypotensive activities of Methadyl Acetate.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Perphenazine.
MethamphetaminePerphenazine may decrease the stimulatory activities of Methamphetamine.
MethapyrileneThe risk or severity of adverse effects can be increased when Perphenazine is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Perphenazine is combined with Methaqualone.
MethocarbamolThe risk or severity of adverse effects can be increased when Perphenazine is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Perphenazine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Perphenazine is combined with Methoxyflurane.
MethsuximideThe risk or severity of adverse effects can be increased when Perphenazine is combined with Methsuximide.
MethylphenidateThe risk or severity of adverse effects can be increased when Perphenazine is combined with Methylphenidate.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Perphenazine.
MetipranololPerphenazine may increase the hypotensive activities of Metipranolol.
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Perphenazine.
MetoprololPerphenazine may increase the hypotensive activities of Metoprolol.
MetoprololThe metabolism of Perphenazine can be decreased when combined with Metoprolol.
MetyrosinePerphenazine may increase the sedative activities of Metyrosine.
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Perphenazine.
MexiletineThe metabolism of Perphenazine can be decreased when combined with Mexiletine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Perphenazine.
MifepristoneThe metabolism of Perphenazine can be decreased when combined with Mifepristone.
MilnacipranThe risk or severity of adverse effects can be increased when Perphenazine is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Perphenazine.
MirabegronThe metabolism of Perphenazine can be decreased when combined with Mirabegron.
MirtazapinePerphenazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Perphenazine.
MitotaneThe serum concentration of Perphenazine can be decreased when it is combined with Mitotane.
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Perphenazine.
ModafinilThe serum concentration of Perphenazine can be decreased when it is combined with Modafinil.
MolindoneThe risk or severity of adverse effects can be increased when Perphenazine is combined with Molindone.
MorphinePerphenazine may increase the hypotensive activities of Morphine.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Perphenazine.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Perphenazine.
NabiloneThe risk or severity of adverse effects can be increased when Perphenazine is combined with Nabilone.
NadololPerphenazine may increase the hypotensive activities of Nadolol.
NafcillinThe serum concentration of Perphenazine can be decreased when it is combined with Nafcillin.
NalbuphinePerphenazine may increase the hypotensive activities of Nalbuphine.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Perphenazine.
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Perphenazine.
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Perphenazine.
NelfinavirThe metabolism of Perphenazine can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Perphenazine can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Perphenazine can be decreased when combined with Nevirapine.
NicardipineThe metabolism of Perphenazine can be decreased when combined with Nicardipine.
NilotinibThe metabolism of Perphenazine can be decreased when combined with Nilotinib.
NitrazepamThe risk or severity of adverse effects can be increased when Perphenazine is combined with Nitrazepam.
Nitrous oxideThe risk or severity of adverse effects can be increased when Perphenazine is combined with Nitrous oxide.
NormethadonePerphenazine may increase the hypotensive activities of Normethadone.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Perphenazine.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Perphenazine.
OlanzapineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Olanzapine.
OlaparibThe metabolism of Perphenazine can be decreased when combined with Olaparib.
OlopatadineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Olopatadine.
OmeprazoleThe metabolism of Perphenazine can be decreased when combined with Omeprazole.
OndansetronThe risk or severity of adverse effects can be increased when Perphenazine is combined with Ondansetron.
OpiumPerphenazine may increase the hypotensive activities of Opium.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Perphenazine.
OrphenadrinePerphenazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Perphenazine.
OsanetantThe risk or severity of adverse effects can be increased when Perphenazine is combined with Osanetant.
OsimertinibThe serum concentration of Perphenazine can be increased when it is combined with Osimertinib.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Perphenazine.
OxprenololPerphenazine may increase the hypotensive activities of Oxprenolol.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Perphenazine.
OxybuprocaineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Oxybuprocaine.
OxycodonePerphenazine may increase the hypotensive activities of Oxycodone.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Perphenazine.
OxymorphonePerphenazine may increase the hypotensive activities of Oxymorphone.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Perphenazine.
PalbociclibThe serum concentration of Perphenazine can be increased when it is combined with Palbociclib.
PaliperidoneThe risk or severity of adverse effects can be increased when Perphenazine is combined with Paliperidone.
PanobinostatThe metabolism of Perphenazine can be decreased when combined with Panobinostat.
PantoprazoleThe metabolism of Perphenazine can be decreased when combined with Pantoprazole.
ParaldehydePerphenazine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Perphenazine.
ParoxetineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Paroxetine.
Peginterferon alfa-2bThe serum concentration of Perphenazine can be decreased when it is combined with Peginterferon alfa-2b.
PenbutololPerphenazine may increase the hypotensive activities of Penbutolol.
PentazocinePerphenazine may increase the hypotensive activities of Pentazocine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Perphenazine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Perphenazine.
PerampanelThe risk or severity of adverse effects can be increased when Perphenazine is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Perphenazine is combined with Perospirone.
PethidinePerphenazine may increase the hypotensive activities of Pethidine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Perphenazine.
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Perphenazine.
PhenobarbitalThe risk or severity of adverse effects can be increased when Perphenazine is combined with Phenobarbital.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Perphenazine is combined with Phenoxyethanol.
PhenterminePerphenazine may decrease the stimulatory activities of Phentermine.
PhenytoinThe risk or severity of adverse effects can be increased when Perphenazine is combined with Phenytoin.
PimozideThe risk or severity of adverse effects can be increased when Perphenazine is combined with Pimozide.
PindololPerphenazine may increase the hypotensive activities of Pindolol.
PioglitazoneThe metabolism of Perphenazine can be decreased when combined with Pioglitazone.
PipamperoneThe risk or severity of adverse effects can be increased when Perphenazine is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Perphenazine is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Perphenazine is combined with Pomalidomide.
PosaconazoleThe metabolism of Perphenazine can be decreased when combined with Posaconazole.
PractololPerphenazine may increase the hypotensive activities of Practolol.
PramipexolePerphenazine may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Perphenazine is combined with Prazepam.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Perphenazine.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Perphenazine.
PrimaquineThe serum concentration of Perphenazine can be increased when it is combined with Primaquine.
PrimidoneThe risk or severity of adverse effects can be increased when Perphenazine is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Perphenazine.
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Perphenazine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Perphenazine.
ProguanilThe serum concentration of Perphenazine can be increased when it is combined with Proguanil.
PromazineThe metabolism of Perphenazine can be decreased when combined with Promazine.
PromazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Promazine.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Perphenazine.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Perphenazine.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Perphenazine.
PropoxycaineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Propoxycaine.
PropranololPerphenazine may increase the hypotensive activities of Propranolol.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Perphenazine.
PSD502The risk or severity of adverse effects can be increased when Perphenazine is combined with PSD502.
PyrimethamineThe serum concentration of Perphenazine can be increased when it is combined with Pyrimethamine.
QuazepamThe serum concentration of Perphenazine can be increased when it is combined with Quazepam.
QuazepamThe risk or severity of adverse effects can be increased when Perphenazine is combined with Quazepam.
QuetiapineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Quetiapine.
QuinacrineThe serum concentration of Perphenazine can be increased when it is combined with Quinacrine.
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Perphenazine.
QuinidineThe serum concentration of Perphenazine can be increased when it is combined with Quinidine.
QuinineThe serum concentration of Perphenazine can be increased when it is combined with Quinine.
RabeprazoleThe metabolism of Perphenazine can be decreased when combined with Rabeprazole.
RadicicolThe serum concentration of Perphenazine can be increased when it is combined with Radicicol.
RamelteonThe risk or severity of adverse effects can be increased when Perphenazine is combined with Ramelteon.
RanolazineThe metabolism of Perphenazine can be decreased when combined with Ranolazine.
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Perphenazine.
RemifentanilPerphenazine may increase the hypotensive activities of Remifentanil.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Perphenazine.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Perphenazine.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Perphenazine.
RifabutinThe metabolism of Perphenazine can be increased when combined with Rifabutin.
RifampicinThe metabolism of Perphenazine can be increased when combined with Rifampicin.
RifapentineThe metabolism of Perphenazine can be increased when combined with Rifapentine.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Perphenazine.
RitonavirThe metabolism of Perphenazine can be decreased when combined with Ritonavir.
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Perphenazine.
RolapitantThe metabolism of Perphenazine can be decreased when combined with Rolapitant.
RomifidineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Romifidine.
RopinirolePerphenazine may increase the sedative activities of Ropinirole.
RopiniroleThe metabolism of Perphenazine can be decreased when combined with Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Perphenazine.
RosiglitazoneThe metabolism of Perphenazine can be decreased when combined with Rosiglitazone.
RotigotinePerphenazine may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Perphenazine.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Perphenazine is combined with S-Ethylisothiourea.
SaquinavirThe metabolism of Perphenazine can be decreased when combined with Saquinavir.
ScopolamineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Perphenazine.
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Perphenazine.
SertindoleThe risk or severity of adverse effects can be increased when Perphenazine is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Perphenazine is combined with Sevoflurane.
SildenafilThe metabolism of Perphenazine can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Perphenazine can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Perphenazine can be increased when it is combined with Simeprevir.
SinefunginThe serum concentration of Perphenazine can be increased when it is combined with Sinefungin.
Sodium oxybateThe risk or severity of adverse effects can be increased when Perphenazine is combined with Sodium oxybate.
SorafenibThe metabolism of Perphenazine can be decreased when combined with Sorafenib.
SotalolPerphenazine may increase the hypotensive activities of Sotalol.
St. John's WortThe serum concentration of Perphenazine can be decreased when it is combined with St. John's Wort.
StiripentolThe risk or severity of adverse effects can be increased when Perphenazine is combined with Stiripentol.
SufentanilPerphenazine may increase the hypotensive activities of Sufentanil.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Perphenazine.
SulfadiazineThe metabolism of Perphenazine can be decreased when combined with Sulfadiazine.
SulfadoxineThe serum concentration of Perphenazine can be increased when it is combined with Sulfadoxine.
SulfamethoxazoleThe metabolism of Perphenazine can be decreased when combined with Sulfamethoxazole.
SulfametopyrazineThe serum concentration of Perphenazine can be increased when it is combined with Sulfametopyrazine.
SulfisoxazoleThe metabolism of Perphenazine can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Perphenazine is combined with Sulpiride.
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Perphenazine.
SuvorexantThe risk or severity of adverse effects can be increased when Perphenazine is combined with Suvorexant.
tafenoquineThe serum concentration of Perphenazine can be increased when it is combined with tafenoquine.
TamoxifenThe metabolism of Perphenazine can be decreased when combined with Tamoxifen.
TapentadolPerphenazine may increase the hypotensive activities of Tapentadol.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Perphenazine.
TasimelteonThe risk or severity of adverse effects can be increased when Perphenazine is combined with Tasimelteon.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Perphenazine.
TelaprevirThe metabolism of Perphenazine can be decreased when combined with Telaprevir.
TelithromycinThe metabolism of Perphenazine can be decreased when combined with Telithromycin.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Perphenazine.
TenofovirThe metabolism of Perphenazine can be decreased when combined with Tenofovir.
TerbinafineThe metabolism of Perphenazine can be decreased when combined with Terbinafine.
TeriflunomideThe serum concentration of Perphenazine can be decreased when it is combined with Teriflunomide.
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Perphenazine.
TetracaineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Perphenazine is combined with Tetrodotoxin.
ThalidomidePerphenazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Perphenazine.
TheophyllineThe metabolism of Perphenazine can be decreased when combined with Theophylline.
ThiamylalThe risk or severity of adverse effects can be increased when Perphenazine is combined with Thiamylal.
ThiopentalThe risk or severity of adverse effects can be increased when Perphenazine is combined with Thiopental.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Perphenazine.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Perphenazine.
ThiotepaThe metabolism of Perphenazine can be decreased when combined with Thiotepa.
ThiothixeneThe risk or severity of adverse effects can be increased when Perphenazine is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Tiagabine.
TicagrelorThe metabolism of Perphenazine can be decreased when combined with Ticagrelor.
TiclopidineThe metabolism of Perphenazine can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Tiletamine.
TimololPerphenazine may increase the hypotensive activities of Timolol.
TipranavirThe metabolism of Perphenazine can be decreased when combined with Tipranavir.
TizanidineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Tizanidine.
TocilizumabThe serum concentration of Perphenazine can be decreased when it is combined with Tocilizumab.
TolbutamideThe metabolism of Perphenazine can be decreased when combined with Tolbutamide.
TolcaponeThe risk or severity of adverse effects can be increased when Perphenazine is combined with Tolcapone.
TopiramateThe risk or severity of adverse effects can be increased when Perphenazine is combined with Topiramate.
TramadolPerphenazine may increase the hypotensive activities of Tramadol.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Perphenazine.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Perphenazine.
TrazodoneThe risk or severity of adverse effects can be increased when Perphenazine is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Perphenazine is combined with Triazolam.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Perphenazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Perphenazine.
TrimethoprimThe serum concentration of Perphenazine can be increased when it is combined with Trimethoprim.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Perphenazine.
TriprolidineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Triprolidine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Perphenazine.
ValsartanThe metabolism of Perphenazine can be decreased when combined with Valsartan.
VemurafenibThe serum concentration of Perphenazine can be increased when it is combined with Vemurafenib.
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Perphenazine.
VerapamilThe metabolism of Perphenazine can be decreased when combined with Verapamil.
VigabatrinThe risk or severity of adverse effects can be increased when Perphenazine is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Perphenazine is combined with Vilazodone.
VoriconazoleThe metabolism of Perphenazine can be decreased when combined with Voriconazole.
VortioxetineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Xylazine.
ZafirlukastThe metabolism of Perphenazine can be decreased when combined with Zafirlukast.
ZaleplonThe risk or severity of adverse effects can be increased when Perphenazine is combined with Zaleplon.
ZiconotideThe risk or severity of adverse effects can be increased when Perphenazine is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Zimelidine.
ZiprasidoneThe metabolism of Perphenazine can be decreased when combined with Ziprasidone.
ZiprasidoneThe risk or severity of adverse effects can be increased when Perphenazine is combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Perphenazine is combined with Zolazepam.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Perphenazine.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Perphenazine.
ZonisamideThe risk or severity of adverse effects can be increased when Perphenazine is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Perphenazine is combined with Zopiclone.
ZotepineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Perphenazine is combined with Zuclopenthixol.
Food Interactions
  • Avoid alcohol.
  • Do not take calcium, aluminum, magnesium or Iron supplements within 2 hours of taking this medication.
  • Take with food.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Seeman P: Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002 Feb;47(1):27-38. [PubMed:11873706 ]
  2. Hoyberg OJ, Fensbo C, Remvig J, Lingjaerde O, Sloth-Nielsen M, Salvesen I: Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations. Acta Psychiatr Scand. 1993 Dec;88(6):395-402. [PubMed:7508675 ]
  3. Qin ZH, Weiss B: Dopamine receptor blockade increases dopamine D2 receptor and glutamic acid decarboxylase mRNAs in mouse substantia nigra. Eur J Pharmacol. 1994 Sep 15;269(1):25-33. [PubMed:7828655 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  5. Talvik M, Nordstrom AL, Larsen NE, Jucaite A, Cervenka S, Halldin C, Farde L: A cross-validation study on the relationship between central D2 receptor occupancy and serum perphenazine concentration. Psychopharmacology (Berl). 2004 Sep;175(2):148-53. Epub 2004 Mar 6. [PubMed:15007534 ]
  6. Farde L, Wiesel FA, Nordstrom AL, Sedvall G: D1- and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics. Psychopharmacology (Berl). 1989;99 Suppl:S28-31. [PubMed:2573104 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD1
Uniprot ID:
P21728
Molecular Weight:
49292.765 Da
References
  1. Dolzan V, Plesnicar BK, Serretti A, Mandelli L, Zalar B, Koprivsek J, Breskvar K: Polymorphisms in dopamine receptor DRD1 and DRD2 genes and psychopathological and extrapyramidal symptoms in patients on long-term antipsychotic treatment. Am J Med Genet B Neuropsychiatr Genet. 2007 Sep 5;144B(6):809-15. [PubMed:17455212 ]
  2. Farde L, Wiesel FA, Nordstrom AL, Sedvall G: D1- and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics. Psychopharmacology (Berl). 1989;99 Suppl:S28-31. [PubMed:2573104 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Titin binding
Specific Function:
Calmodulin mediates the control of a large number of enzymes, ion channels, aquaporins and other proteins by Ca(2+). Among the enzymes to be stimulated by the calmodulin-Ca(2+) complex are a number of protein kinases and phosphatases. Together with CCP110 and centrin, is involved in a genetic pathway that regulates the centrosome cycle and progression through cytokinesis.
Gene Name:
CALM1
Uniprot ID:
P62158
Molecular Weight:
16837.47 Da
References
  1. Mongin AA, Cai Z, Kimelberg HK: Volume-dependent taurine release from cultured astrocytes requires permissive [Ca(2+)](i) and calmodulin. Am J Physiol. 1999 Oct;277(4 Pt 1):C823-32. [PubMed:10516112 ]
  2. Kawai M, Nakashima A, Ueno M, Ushimaru T, Aiba K, Doi H, Uritani M: Fission yeast tor1 functions in response to various stresses including nitrogen starvation, high osmolarity, and high temperature. Curr Genet. 2001 May;39(3):166-74. [PubMed:11409178 ]
  3. Edlind T, Smith L, Henry K, Katiyar S, Nickels J: Antifungal activity in Saccharomyces cerevisiae is modulated by calcium signalling. Mol Microbiol. 2002 Oct;46(1):257-68. [PubMed:12366848 ]
  4. Natochin YuV, Shakhmatova EI, Bakos P: Water and sodium transport: effects of calcium channel blocker and calmodulin antagonists on the apical and basolateral membranes of amphibian epithelia. Gen Physiol Biophys. 1987 Feb;6(1):35-44. [PubMed:2885243 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Otani K, Aoshima T: Pharmacogenetics of classical and new antipsychotic drugs. Ther Drug Monit. 2000 Feb;22(1):118-21. [PubMed:10688273 ]
  2. Micallef J, Fakra E, Blin O: [Use of antidepressant drugs in schizophrenic patients with depression]. Encephale. 2006 Mar-Apr;32(2 Pt 1):263-9. [PubMed:16910628 ]
  3. Linnet K, Wiborg O: Steady-state serum concentrations of the neuroleptic perphenazine in relation to CYP2D6 genetic polymorphism. Clin Pharmacol Ther. 1996 Jul;60(1):41-7. [PubMed:8689810 ]
  4. Ozdemir V, Naranjo CA, Herrmann N, Reed K, Sellers EM, Kalow W: Paroxetine potentiates the central nervous system side effects of perphenazine: contribution of cytochrome P4502D6 inhibition in vivo. Clin Pharmacol Ther. 1997 Sep;62(3):334-47. [PubMed:9333110 ]
  5. Hamelin BA, Bouayad A, Drolet B, Gravel A, Turgeon J: In vitro characterization of cytochrome P450 2D6 inhibition by classic histamine H1 receptor antagonists. Drug Metab Dispos. 1998 Jun;26(6):536-9. [PubMed:9616188 ]
  6. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  7. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP2C18
Uniprot ID:
P33260
Molecular Weight:
55710.075 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23